105211-79-8

Upstream product

• 90-00-6 o-Hydroxyethylbenzene 
• 2179-89-7 bis(1,3-diphenyl-2-imidazolidinylidene) 
• 4885-02-3 Dichloromethyl methyl ether 
• 162269-90-1 3-bromo-4-(methoxymethoxy)benzaldehyde 
• 2973-78-6 3-bromo-4-hydroxybenzylaldehyde 
• 97-94-9 triethyl borane 

Downstream Products

• 637353-27-6 ethyl [2-ethyl-4-({(propylsulfonyl)[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino}methyl)pheoxy]acetate 
• 637353-23-2 ethyl {4-[(butyl{6-[4-(trifluoromethyl)phenyl]pyrazin-2-yl}amino)methyl]-2-ethylphenoxy}acetate 
• 637353-25-4 ethyl [4-({butyl[5-methyl-6-(4-methylphenyl)pyrimidin-4-yl]amino}methyl)-2-ethylphenoxy]acetate 
• 637353-20-9 ethyl [2-ethyl-4-({[4'-(trifluoromethyl)-1,1'-biphenyl-3-yl]amino}methyl)phenoxy]acetate 
• 637353-21-0 ethyl {4-[(butylamino)methyl]-2-ethylphenoxy}acetate 
• 637353-18-5 ethyl [2-ethyl-4-(hydroxymethyl)phenoxy]acetate 
• 637353-19-6 ethyl (2-ethyl-4-formylphenoxy)acetate 
• 68658-12-8 2-ethyl-4-(hydroxymethyl)phenol 

Relevant academic research and scientific papers

SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF

The present disclosure relates to substituted hydroxystilbene compounds and derivatives, specifically 2-substituted hydroxystilbene compounds and derivatives, the synthesis of such compounds and their use in therapy.

MACROCYCLIC COMPOUND AND USE THEREOF

A compound represented by the following formula (I): wherein each symbol in the formula is as described herein or a salt thereof has an NRF2 activating activity, and is expected to be useful as a preventive or therapeutic agent for diseases associated with oxidative stress, in particular, hepatic disease (for example, non-alcoholic steatohepatitis (NASH)), cardiovascular disease (for example, heart failure or pulmonary arterial hypertension), lung disease (for example, chronic obstructive pulmonary disease (COPD)), kidney disease (for example, chronic kidney disease (CKD) or acute kidney injury (AKI)), central nervous system disease (for example, Parkinson's disease), mitochondrial disease (for example, Friedreich motor ataxia, mitochondrial myopathy), inflammatory disease (for example, multiple sclerosis (MS), inflammatory bowel disease (IBD)), sickle cell disease, cancer, or the like.

IMMUNE CHECKPOINT INHIBITORS, COMPOSITIONS AND METHODS THEREOF

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula (I), or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. For Formula (I) compounds R1, R2, X1, Y1 and n are as defined in the specification. The inventive Formula (I) compounds are inhibitors of the PD-1/PD-L1 protein/protein binding or functional interaction and find utility in any number of therapeutic applications, including but not limited to treatment of proliferative disorders such as cancer and infectious diseases.

Direct B-alkyl Suzuki-Miyaura cross-coupling of trialkyl-boranes with aryl bromides in the presence of unmasked acidic or basic functions and base-labile protections under mild non-aqueous conditions

An efficient and chemoselective palladium-catalyzed direct B-alkyl Suzuki-Miyaura cross-coupling of trialkylboranes with diversely functionalized aryl bromides is described. A wide variety of unmasked acidic or basic functions are tolerated. The mild non-

AMIDE COMPOUND AND USE OF THE SAME

PROBLEM TO BE SOLVED: To provide a compound having an excellent controlling effect against plant pests. SOLUTION: This amide compound expressed by formula (1) [wherein, R1 is H, a halogen atom, a 1-4C alkyl or the like; R2 is a 1-4C alkyl, a 1-4C haloalkyl or the like; R3 is H or a 1-3C alkyl; R4 is a halogen, a 1-4C alkylthio, a 2-5C alkylcarbonyloxy or the like; R5 is a 3-4C alkynyl; and X is O or S] has the excellent controlling effect against the plant pests. COPYRIGHT: (C)2006,JPOandNCIPI

N-(4- carbamimidoyl-phenyl) -glycine derivatives

The invention is concerned with novel N-(4-carbamimidoyl-phenyl)-glycine derivatives of the formula: wherein R1, E, X1 to X4 and G1 and G2 are as defined in the description and the claims, as well as hydrates or solvates and physiologically usable salts thereof.

Process for selective preparation of hydroxybenzaldehydes

Process for preparing hydroxybenzaldehydes of the formula (1) STR1 in which R1 -R4 are hydrogen, fluorine, chlorine, bromine, alkyl, alkoxy, phenyl, naphthyl, phenylalkyl, naphthylalkyl, phenoxy or saturated or unsaturated cyclopentane or cyclohexane radicals, and R1 -R4 may with the hydroxybenzene ring carbon atoms on which they are located form 1 or 2 saturated or unsaturated isocyclic or heterocyclic rings, by admixing 1 mol of a phenol of the formula (2) STR2 in which R1 -R4 have the stated meanings, in a pressure vessel with from 5 to 100 mol of hydrogen fluoride and from 0.5+x to 1.5+x mol of boron trifluoride, where x is the number of oxygen atoms contained in the starting compound (formula (2)), setting the mixture to from -10° to 100° C. and then passing carbon monoxide into this mixture until a pressure of from 10 to 150 bar is reached and allowing the mixture to react at the desired pressure reached.